Interaction between age and vitamin D deficiency in severe COVID-19 infection

Macaya et al., Nutr. Hosp., doi:10.20960/nh.03193, Oct 2020
Severe case 55% improvement lower risk ← → higher risk Vitamin D for COVID-19  Macaya et al.  SUFFICIENCY   Are vitamin D levels associated with COVID-19 outcomes? Retrospective 80 patients in Spain Lower severe cases with higher vitamin D levels (not stat. sig., p=0.07) c19early.org Macaya et al., Nutr. Hosp., October 2020 0 0.5 1 1.5 2+ RR
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020, now with p < 0.00000000001 from 126 studies, recognized in 18 countries.
No treatment is 100% effective. Protocols combine treatments.
6,200+ studies for 200+ treatments. c19early.org
Retrospective 80 hospitalized patients in Spain showing higher risk of severe COVID-19 with vitamin D deficiency.
This is the 21st of 226 COVID-19 sufficiency studies for vitamin D, which collectively show higher levels reduce risk with p<0.0000000001 (1 in 115,066,047,903,039,356,928 vigintillion).
risk of severe case, 55.0% lower, RR 0.45, p = 0.07, high D levels 11 of 35 (31.4%), low D levels 20 of 45 (44.4%), NNT 7.7, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >20ng/mL.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Macaya et al., 21 Oct 2020, retrospective, Spain, peer-reviewed, 8 authors.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2025 Spain United Kingdom Russia Sudan Angola Colombia Kenya Mozambique Vietnam Peru Philippines China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Georgia Switzerland Bosnia-Herzegovina Ukraine Côte d'Ivoire Bulgaria Greece Slovakia Singapore Iceland New Zealand Czechia Mongolia Israel Trinidad and Tobago Hong Kong North Macedonia Belarus Qatar Panama Serbia CAR Spain favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2025 Spain United Kingdom Russia Sudan Angola Colombia Kenya Mozambique Vietnam Peru Philippines China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Georgia Switzerland Bosnia-Herzegovina Ukraine Côte d'Ivoire Eritrea Bulgaria Greece Slovakia Singapore New Zealand Malawi Czechia Mongolia Israel Trinidad and Tobago North Macedonia Belarus Qatar Panama Serbia Syria Spain favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
DOI record: { "DOI": "10.20960/nh.03193", "ISSN": [ "1699-5198", "0212-1611" ], "URL": "http://dx.doi.org/10.20960/nh.03193", "author": [ { "affiliation": [], "family": "Macaya", "given": "Fernando", "sequence": "first" }, { "affiliation": [], "family": "Espejo Paeres", "given": "Carolina", "sequence": "additional" }, { "affiliation": [], "family": "Valls", "given": "Adrián", "sequence": "additional" }, { "affiliation": [], "family": "Fernández-Ortiz", "given": "Antonio", "sequence": "additional" }, { "affiliation": [], "family": "González del Castillo", "given": "Juan", "sequence": "additional" }, { "affiliation": [], "family": "Martín-Sánchez", "given": "Javier", "sequence": "additional" }, { "affiliation": [], "family": "Runkle", "given": "Isabelle", "sequence": "additional" }, { "affiliation": [], "family": "Rubio Herrera", "given": "Miguel Ángel", "sequence": "additional" } ], "container-title": "Nutrición Hospitalaria", "container-title-short": "Nutr Hosp", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2020, 9, 17 ] ], "date-time": "2020-09-17T14:59:10Z", "timestamp": 1600354750000 }, "deposited": { "date-parts": [ [ 2020, 9, 17 ] ], "date-time": "2020-09-17T14:59:18Z", "timestamp": 1600354758000 }, "indexed": { "date-parts": [ [ 2023, 8, 10 ] ], "date-time": "2023-08-10T17:35:33Z", "timestamp": 1691688933681 }, "is-referenced-by-count": 28, "issued": { "date-parts": [ [ 2020 ] ] }, "member": "8588", "original-title": [], "prefix": "10.20960", "published": { "date-parts": [ [ 2020 ] ] }, "published-print": { "date-parts": [ [ 2020 ] ] }, "publisher": "ARAN Ediciones", "reference": [ { "DOI": "10.3390/nu12010236", "doi-asserted-by": "publisher", "key": "ref1" }, { "DOI": "10.3390/nu12040988", "doi-asserted-by": "publisher", "key": "ref2" }, { "DOI": "10.3892/mmr.2017.7546", "doi-asserted-by": "publisher", "key": "ref3" }, { "DOI": "10.1038/s41430-020-0558-y", "doi-asserted-by": "publisher", "key": "ref4" }, { "DOI": "10.1007/s00394-017-1564-2", "doi-asserted-by": "publisher", "key": "ref5" }, { "DOI": "10.1038/ejcn.2010.265", "doi-asserted-by": "publisher", "key": "ref6" }, { "DOI": "10.1136/thoraxjnl-2014-206680", "doi-asserted-by": "publisher", "key": "ref7" }, { "DOI": "10.1016/S0140-6736(20)30183-5", "doi-asserted-by": "publisher", "key": "ref8" }, { "DOI": "10.1161/CIRCULATIONAHA.120.047659", "doi-asserted-by": "publisher", "key": "ref9" }, { "DOI": "10.3892/mmr.2019.10047", "doi-asserted-by": "publisher", "key": "ref10" }, { "DOI": "10.1210/me.2013-1146", "doi-asserted-by": "crossref", "key": "ref11", "unstructured": "Kong J, Zhu X, Shi Y, Liu T, Chen Y, Bhan I, et al. VDR Attenuates Acute Lung Injury by Blocking Ang-2-Tie-2 Pathway and Renin-Angiotensin System. Molecular Endocrinology 2013;27:2116-25." }, { "DOI": "10.1056/NEJMsr2005760", "doi-asserted-by": "crossref", "key": "ref12", "unstructured": "Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. New England Journal of Medicine 2020;382:1653-9." }, { "DOI": "10.1038/nature03712", "doi-asserted-by": "crossref", "key": "ref13", "unstructured": "Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005;436:112-6." }, { "DOI": "10.3390/nu12051359", "doi-asserted-by": "crossref", "key": "ref14", "unstructured": "D’Avolio A, Avataneo V, Manca A, Cusato J, De Nicolò A, Lucchini R, et al. 25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2. Nutrients 2020;12." }, { "DOI": "10.1007/s40520-020-01570-8", "doi-asserted-by": "crossref", "key": "ref15", "unstructured": "Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clinical and Experimental Research [Internet] 2020 [cited 2020 May 17]. Available from: http://link.springer.com/10.1007/s40520-020-01570-8" }, { "DOI": "10.1186/s40779-020-00240-0", "doi-asserted-by": "crossref", "key": "ref16", "unstructured": "Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Medical Research [Internet] 2020 [cited 2020 May 4]. Available from: https://mmrjournal.biomedcentral.com/articles/10.1186/s40779-020-00240-0" }, { "DOI": "10.3390/ijms21082948", "doi-asserted-by": "crossref", "key": "ref17", "unstructured": "La Vignera S, Cannarella R, Condorelli RA, Torre F, Aversa A, Calogero AE. Sex-Specific SARS-CoV-2 Mortality: Among Hormone-Modulated ACE2 Expression, Risk of Venous Thromboembolism and Hypovitaminosis D. International Journal of Molecular Sciences 2020;21:2948." }, { "DOI": "10.1016/j.respe.2018.05.092", "doi-asserted-by": "crossref", "key": "ref18", "unstructured": "Waldhoer T, Endler G, Yang L, Haidinger G, Wagner O, Marculescu R. Vitamin D deficiency, overall and cause-specific mortality: the impact of age. Revue d’Épidémiologie et de Santé Publique 2018;66:S271." }, { "DOI": "10.4110/in.2019.19.e37", "doi-asserted-by": "crossref", "key": "ref19", "unstructured": "Oh S-J, Lee JK, Shin OS. Aging and the Immune System: the Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity. Immune Network [Internet] 2019 [cited 2020 Apr 26]. Available from: https://synapse.koreamed.org/DOIx.php?id=10.4110/in.2019.19.e37" }, { "DOI": "10.1016/j.endinu.2016.11.002", "doi-asserted-by": "crossref", "key": "ref20", "unstructured": "Varsavsky M, Rozas Moreno P, Becerra Fernández A, Luque Fernández I, Quesada Gómez JM, Ávila Rubio V, et al. Recomendaciones de vitamina D para la población general. Endocrinología, Diabetes y Nutrición 2017;64:7-14." } ], "reference-count": 20, "references-count": 20, "relation": {}, "resource": { "primary": { "URL": "https://www.nutricionhospitalaria.org/articles/03193/show" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Nutrition and Dietetics", "Medicine (miscellaneous)" ], "subtitle": [], "title": "Interaction between age and vitamin D deficiency in severe COVID-19 infection", "type": "journal-article" }
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit